The effect of C1-esterase inhibitor on systemic inflammation in trauma patients with a femur fracture - The CAESAR study: study protocol for a randomized controlled trial

Trials

Luke PH Leenen¹  Leo Koenderman²  Paul FW Strengers³  Anky HL Koenderman³  Karlijn JP van Wessem¹  Tjaakje Visser¹  Marjolein Heeres² 

[1] Department of Trauma Surgery, University Medical Centre Utrecht, Heidelberglaan 100, 3508 GA, Utrecht, The Netherlands;Department of Respiratory Medicine, University Medical Centre Utrecht, Heidelberglaan 100, 3508 GA, Utrecht, The Netherlands;Sanquin Blood Supply Foundation, Plesmanlaan 125, 1066 CX, Amsterdam, The Netherlands

关键词: Trauma;    MODS;    Intramedullary fixation;    Interleukin-6;    Inflammation;    Fracture;    Femur;    Complication;    C1-esterase inhibitor;    ARDS;   

Others  :  1095826
DOI  :  10.1186/1745-6215-12-223

 received in 2011-07-25, accepted in 2011-10-11,  发布年份 2011

【 摘 要 】

Background

Systemic inflammation in response to a femur fracture and the additional fixation is associated with inflammatory complications, such as acute respiratory distress syndrome and multiple organ dysfunction syndrome. The injury itself, but also the additional procedure of femoral fixation induces a release of pro-inflammatory cytokines such as interleukin-6. This results in an aggravation of the initial systemic inflammatory response, and can cause an increased risk for the development of inflammatory complications. Recent studies have shown that administration of the serum protein C1-esterase inhibitor can significantly reduce the release of circulating pro-inflammatory cytokines in response to acute systemic inflammation.

Objective

Attenuation of the surgery-induced additional systemic inflammatory response by perioperative treatment with C1-esterase inhibitor of trauma patients with a femur fracture.

Methods

The study is designed as a double-blind randomized placebo-controlled trial. Trauma patients with a femur fracture, Injury Severity Score ≥ 18 and age 18-80 years are included after obtaining informed consent. They are randomized for administration of 200 U/kg C1-esterase inhibitor intravenously or placebo (saline 0.9%) just before the start of the procedure of femoral fixation. The primary endpoint of the study is Δ interleukin-6, measured at t = 0, just before start of the femur fixation surgery and administration of C1-esterase inhibitor, and t = 6, 6 hours after administration of C1-esterase inhibitor and the femur fixation.

Conclusion

This study intents to identify C1-esterase inhibitor as a safe and potent anti-inflammatory agent, that is capable of suppressing systemic inflammation in trauma patients. This might facilitate early total care procedures by lowering the risk of inflammation in response to the surgical intervention. This could result in increased functional outcomes and reduced health care related costs.

Trial registration

clinicaltrials.gov NCT01275976 (January 12th 2011)

【 授权许可】

   
2011 Heeres et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Hietbrink F, Koenderman L, Rijkers G, Leenen L: Trauma: the role of the innate immune system. World J Emerg Surg 2006, 1:15. BioMed Central Full Text
• [2]Hietbrink F, Oudijk EJ, Braams R, Koenderman L, Leenen L: Aberrant regulation of polymorphonuclear phagocyte responsiveness in multitrauma patients. Shock 2006, 26(6):558-564.
• [3]Pillay J, Hietbrink F, Koenderman L, Leenen LP: The systemic inflammatory response induced by trauma is reflected by multiple phenotypes of blood neutrophils. Injury 2007, 38(12):1365-1372.
• [4]Ulvik A, Kvale R, Wentzel-Larsen T, Flaatten H: Multiple organ failure after trauma affects even long-term survival and functional status. Crit Care 2007, 11(5):R95..
• [5]Lenz A, Franklin GA, Cheadle WG: Systemic inflammation after trauma. Injury 2007, 38(12):1336-1345.
• [6]Cruickshank AM, Fraser WD, Burns HJ, Van Damme J, Shenkin A: Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci (Lond) 1990, 79(2):161-165.
• [7]Giannoudis PV, Smith RM, Bellamy MC, Morrison JF, Dickson RA, Guillou PJ: Stimulation of the inflammatory system by reamed and unreamed nailing of femoral fractures. An analysis of the second hit. J Bone Joint Surg Br 1999, 81(2):356-361.
• [8]Gebhard F, Pfetsch H, Steinbach G, Strecker W, Kinzl L, Bruckner UB: Is interleukin 6 an early marker of injury severity following major trauma in humans? Arch Surg 2000, 135(3):291-295.
• [9]Giannoudis PV, Harwood PJ, Loughenbury P, Van Griensven M, Krettek C, Pape HC: Correlation between IL-6 levels and the systemic inflammatory response score: can an IL-6 cutoff predict a SIRS state? J Trauma 2008, 65(3):646-652.
• [10]Kobbe P, Vodovotz Y, Kaczorowski DJ, Mollen KP, Billiar TR, Pape HC: Patterns of cytokine release and evolution of remote organ dysfunction after bilateral femur fracture. Shock 2008, 30(1):43-47.
• [11]Pape HC, Griensven MV, Hildebrand FF, Tzioupis CT, Sommer KL, Krettek CC, Giannoudis PV: Systemic inflammatory response after extremity or truncal fracture operations. J Trauma 2008, 65(6):1379-1384.
• [12]Morley JR, Smith RM, Pape HC, MacDonald DA, Trejdosiewitz LK, Giannoudis PV: Stimulation of the local femoral inflammatory response to fracture and intramedullary reaming: a preliminary study of the source of the second hit phenomenon. J Bone Joint Surg Br 2008, 90(3):393-399.
• [13]Pape HC, Van Griensven M, Rice J, Gansslen A, Hildebrand F, Zech S, Winny M, Lichtinghagen R, Krettek C: Major secondary surgery in blunt trauma patients and perioperative cytokine liberation: determination of the clinical relevance of biochemical markers. J Trauma 2001, 50(6):989-1000.
• [14]Tschoeke SK, Hellmuth M, Hostmann A, Ertel W, Oberholzer A: The early second hit in trauma management augments the proinflammatory immune response to multiple injuries. J Trauma 2007, 62(6):1396-1403.
• [15]Pape HC, Giannoudis P, Krettek C: The timing of fracture treatment in polytrauma patients: relevance of damage control orthopedic surgery. Am J Surg 2002, 183(6):622-629.
• [16]Pape HC: Effects of changing strategies of fracture fixation on immunologic changes and systemic complications after multiple trauma: damage control orthopedic surgery. J Orthop Res 2008, 26(11):1478-1484.
• [17]Pape HC, Grimme K, Van Griensven M, Sott AH, Giannoudis P, Morley J, Roise O, Ellingsen E, Hildebrand F, Wiebe B, Krettek C: Impact of intramedullary instrumentation versus damage control for femoral fractures on immunoinflammatory parameters: prospective randomized analysis by the EPOFF Study Group. J Trauma 2003, 55(1):7-13.
• [18]Morshed S, Miclau T III, Bembom O, Cohen M, Knudson MM, Colford JM Jr: Delayed internal fixation of femoral shaft fracture reduces mortality among patients with multisystem trauma. J Bone Joint Surg Am 2009, 91(1):3-13.
• [19]Pape HC, Hildebrand F, Pertschy S, Zelle B, Garapati R, Grimme K, Krettek C, Reed RL: Changes in the management of femoral shaft fractures in polytrauma patients: from early total care to damage control orthopedic surgery. J Trauma 2002, 53(3):452-461.
• [20]Pape HC, Tsukamoto T, Kobbe P, Tarkin I, Katsoulis S, Peitzman A: Assessment of the clinical course with inflammatory parameters. Injury 2007, 38(12):1358-1364.
• [21]Dorresteijn MJ, Visser T, Cox LA, Bouw MP, Pillay J, Koenderman AH, Strengers PF, Leenen LP, van der Hoeven JG, Koenderman L, Pickkers P: C1-esterase inhibitor attenuates the inflammatory response during human endotoxemia. Crit Care Med 2010, 38(11):2139-2145.
• [22]Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE: C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000, 52(1):91-112.
• [23]Zeerleder S, Caliezi C, van Mierlo G, Eerenberg-Belmer A, Sulzer I, Hack CE, Wuillemin WA: Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. Clin Diagn Lab Immunol 2003, 10(4):529-535.
• [24]Liu D, Lu F, Qin G, Fernandes SM, Li J, Davis AE III: C1 inhibitor-mediated protection from sepsis. J Immunol 2007, 179(6):3966-3972.
• [25]Bahador M, Cross AS: From therapy to experimental model: a hundred years of endotoxin administration to human subjects. J Endotoxin Res 2007, 13(5):251-279.
• [26]The Declaration of Helsinki (September 20th 2011) [http://www.wma.net/en/30publications/10policies/b3/ webcite]
• [27]The Good Clinical Practice Guidelines (September 20th 2011) [http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf webcite]
• [28]Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101(6):1644-1655.
• [29]Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 1998, 26(11):1793-1800.
• [30]Maier B, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, Marzi I: Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. Shock 2007, 28(6):668-674.
• [31]Stensballe J, Christiansen M, Tonnesen E, Espersen K, Lippert FK, Rasmussen LS: The early IL-6 and IL-10 response in trauma is correlated with injury severity and mortality. Acta Anaesthesiol Scand 2009, 53(4):515-521.
• [32]Bull K, Spiegelhalter DJ: Survival analysis in observational studies. Stat Med 1997, 16(9):1041-1074.
• [33]O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 1979, 35(3):549-556.
• [34]Kirschfink M, Nurnberger W: C1 inhibitor in anti-inflammatory therapy: from animal experiment to clinical application. Mol Immunol 1999, 36(4-5):225-232.
• [35]Wouters D, Wagenaar-Bos I, van Ham M, Zeerleder S: C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. Expert Opin Biol Ther 2008, 8(8):1225-1240.
• [36]Kirschfink M, Mollnes TE: C1-inhibitor: an anti-inflammatory reagent with therapeutic potential. Expert Opin Pharmacother 2001, 2(7):1073-1083.
• [37]Nuijens JH, Eerenberg-Belmer AJ, Huijbregts CC, Schreuder WO, Felt-Bersma RJ, Abbink JJ, Thijs LG, Hack CE: Proteolytic inactivation of plasma C1- inhibitor in sepsis. J Clin Invest 1989, 84(2):443-450.
• [38]de Zwaan C, Kleine AH, Diris JH, Glatz JF, Wellens HJ, Strengers PF, Tissing M, Hack CE, van Dieijen-Visser MP, Hermens WT: Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 2002, 23(21):1670-1677.
• [39]Struber M, Hagl C, Hirt SW, Cremer J, Harringer W, Haverich A: C1-esterase inhibitor in graft failure after lung transplantation. Intensive Care Med 1999, 25(11):1315-1318.